Spots Global Cancer Trial Database for Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies
Official Title: A Phase II Trial of Consolidation Chemothetapy for Patients With Relapse or Refractory Lymphoid Malignancies After Autologous Stem Cell Transplantation
Study ID: NCT02306837
Conditions
Interventions
Study Description
Brief Summary: To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation
Detailed Description: Patients with relapsed or refractory lymphoma will be included. All patients will undergo PBSC mobilization with CTX and G-CSF. After sucessful collection of CD34+ over 1x109/L, autologous stem cel ltransplantation with Bu-Cy-E conditioning will be given. Two months after auto-HSCT, a PET-CT will be performed and all patients with CR, CRu and PR will recieved 3 cycles of mini-Bu-Cy-E as consolidation 3, 6 and 9 months after auto-HSCT. For patients with SD or PD after auto-HSCT will refered to the allogeneic transplantatio program and take off the study.
Eligibility
Minimum Age: 16 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rui Jin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, , China
Shanghai No 10 Hospital, Shanghai, , China
Contact Details
Name: Jiong Hu, M.D,
Affiliation: Rui Jin Hospital, Shanghai Jiaotong Unic\versity School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
